Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma

(2018) Erik Ladomersky et al.   CLINICAL CANCER RESEARCH

Regulation of the Immune Response by the Aryl Hydrocarbon Receptor

(2018) Cristina Gutiérrez-Vázquez et al.   IMMUNITY

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2

(2018) Avinoam Nevler et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities

(2018) Jae Eun Cheong et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

(2017) Eddy W. Yue et al.   ACS Medicinal Chemistry Letters

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

(2016) Henrique Lemos et al.   CANCER RESEARCH

Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies

(2016) A. M. Monjazeb et al.   CLINICAL CANCER RESEARCH

IDO1 is an Integral Mediator of Inflammatory Neovascularization

(2016) Arpita Mondal et al.   EBioMedicine

A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer

(2015) Nicholas C. D'Amato et al.   CANCER RESEARCH

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer

(2015) A. J. Gunderson et al.   Cancer Discovery

Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia

(2015) K. E. Lee et al.   Cancer Discovery

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

(2014) I. Theate et al.   Cancer Immunology Research

IDO2 in Immunomodulation and Autoimmune Disease

(2014) George C. Prendergast et al.   Frontiers in Immunology

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

(2014) Minghui Li et al.   Journal for ImmunoTherapy of Cancer

Small molecule modulators of eukaryotic initiation factor 2α kinases, the key regulators of protein synthesis

(2013) Manali Joshi et al.   BIOCHIMIE

Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive T-cells

(2013) Theodoros Eleftheriadis et al.   HUMAN IMMUNOLOGY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target

(2013) Stephen Safe et al.   TOXICOLOGICAL SCIENCES

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

(2012) Richard Metz et al.   OncoImmunology

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

(2011) Yan-Jie Zhang et al.   DRUG DISCOVERY TODAY

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Why tumours eat tryptophan

(2011) George C. Prendergast   NATURE

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate

(2010) A. J. Muller et al.   CANCER RESEARCH

Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation

(2010) Alexander J Muller et al.   Immunotherapy

Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target

(2009) Agnieszka K. Witkiewicz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Infectious tolerance via the consumption of essential amino acids and mTOR signaling

(2009) S. P. Cobbold et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

(2008) Stefan Löb et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection

(2008) Agnes Witkiewicz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase

(2008) A. J. Muller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA